A Phase 4 interventional study of Celecoxib 100 MG and Celecoxib 200mg in Osteoarthritis Hand, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-30.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing celecoxib in Osteoarthritis — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis.
Among the 14 studies testing celecoxib in Osteoarthritis, this one is the 9th largest by enrollment, is the only one that started in 2016, is one of 10 in phase 4, and was the 13th registered.
2,975 studies on the registry are indexed under Osteoarthritis; 435 are open to participants now.
Browse Osteoarthritis studies →1 of the 14 studies testing celecoxib in Osteoarthritis is open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 41+
By country, each count listing its studies:
Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 19 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is above the median of 80 across 2,239 interventional studies indexed under Osteoarthritis.
Median enrollment 150 across the 14 interventional studies. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 9 most frequent:
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.
Chong Kun Dang Pharmaceutical has 1 study filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing celecoxib in Osteoarthritis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate efficacy and safety of Celecoxib capsule in hand osteoarthritis patients.
This is a six-weeks, open-label, multi-center, randomized study. Patients take Celecoxib 200mg capsule once a day or Celecoxib 100mg capsules twice per day. If patients do not tolerate the pain, they are able to take Acetaminophen as a rescue medication during 6 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Who had following results after examination
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
Drug: Celecoxib 100 MG
Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
Drug: Celecoxib 200mg
Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
Also known as: Celecoxib 100mg capsule
Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
Also known as: Celecoxib 200mg capsule
The change of 100mm Pain VAS score at 6 weeks relative to the baseline value of each group
Time frame: baseline, 6weeks
Changes in each item of K-AUSCAN at 6 weeks relative to the baseline value of each group
Time frame: baseline, 6weeks
The total point change of K-AUSCAN at 6 weeks relative to the baseline value of each group
Time frame: baseline, 6weeks
Total score change of insomnia severity at 6 weeks relative to the baseline value of each group
Time frame: baseline, 6weeks
Total dosing days of acetaminophen for 6 weeks in each group
Time frame: 6weeks
The total dose of acetaminophen for 6 weeks in each group
Time frame: 6weeks
Percentage of subjects using acetaminophen for 6 weeks in each group
Time frame: 6weeks
Safety assessed by the incidence of adverse event
Time frame: up to 6weeks
laboratory test(Hematology test, Blood chemistry test, Urinalysis)
Time frame: up to 6weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Dec 2016 to primary completion in Jul 2017, 6 months.
Of 63 phase 4 interventional studies under Osteoarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 60. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Chong Kun Dang Pharmaceutical →